Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.
Hector S IzurietaXiyuan WuRichard ForsheeYun LuHeng-Ming SungPaula Ehrlich AggerYoganand ChillarigeRuth Link-GellesBradley LufkinMichael WerneckeThomas E MaCurdyJeffrey KelmanKathleen DoolingPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
This large real-world observational study of the effectiveness of Shingrix demonstrates the benefit of completing the 2-dose regimen. Second doses administered beyond the recommended 6 months did not impair effectiveness. Our effectiveness estimates were lower than the clinical trials estimates, likely due to differences in outcome specificity.